Spotlight
Clinical
Events
CME
Partners
Subscribe
- COVID-19
- Biosimilars
- Cataract Therapeutics
- DME
- Gene Therapy
- Workplace
- Ptosis
- Optic Relief
- Imaging
- Geographic Atrophy
- AMD
- Presbyopia
- Ocular Surface Disease
- Practice Management
- Pediatrics
- Surgery
- Therapeutics
- Optometry
- Retina
- Cataract
- Pharmacy
- IOL
- Dry Eye
- Understanding Antibiotic Resistance
- Refractive
- Cornea
- Glaucoma
- OCT
- Ocular Allergy
- Clinical Diagnosis
- Technology
FDA approves new hyaluronidase formula
Rockville, MD—The FDA has approved PrimaPharm Inc.'s new drug application for a new formulation for hyaluronidase injection (Hydase).
Rockville, MD-The FDA has approved PrimaPharm Inc.'s new drug application for a new formulation for hyaluronidase injection (Hydase).
The prescription drug was approved as an adjuvant to increase the absorption and dispersion of other injected drugs, for hypodermoclysis, and as an adjunct in subcutaneous urography for improving resorption of radiopaque agents.
The FDA said it is a proteolytic enzyme and reviewed under a priority review cycle.
Related Videos
Related Content
